These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29948930)

  • 1. Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR.
    Sosa-Eroza E; Espinosa E; Ramírez-Rentería C; Mendoza V; Arreola R; Mercado M
    Endocrine; 2018 Aug; 61(2):343-348. PubMed ID: 29948930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma.
    Fusco A; Lugli F; Sacco E; Tilaro L; Bianchi A; Angelini F; Tofani A; Barini A; Lauriola L; Maira G; Pontecorvi A; de Marinis L
    Pituitary; 2011 Dec; 14(4):351-7. PubMed ID: 19152032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
    Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
    Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR.
    Vilar L; Azevedo MF; Naves LA; Casulari LA; Albuquerque JL; Montenegro RM; Montenegro RM; Figueiredo P; Nascimento GC; Faria MS
    Pituitary; 2011 Jun; 14(2):148-56. PubMed ID: 21104199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
    Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
    Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion.
    Cuny T; Mohamed A; Graillon T; Roche C; Defilles C; Germanetti AL; Couderc B; Figarella-Branger D; Enjalbert A; Barlier A; Saveanu A
    Mol Cell Endocrinol; 2012 May; 355(1):106-13. PubMed ID: 22348806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
    Vroonen L; Jaffrain-Rea ML; Petrossians P; Tamagno G; Chanson P; Vilar L; Borson-Chazot F; Naves LA; Brue T; Gatta B; Delemer B; Ciccarelli E; Beck-Peccoz P; Caron P; Daly AF; Beckers A
    Eur J Endocrinol; 2012 Nov; 167(5):651-62. PubMed ID: 22918301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.
    Jaquet P; Gunz G; Saveanu A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Enjalbert A; Culler MD
    Eur J Endocrinol; 2005 Jul; 153(1):135-41. PubMed ID: 15994755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
    Suda K; Inoshita N; Iguchi G; Fukuoka H; Takahashi M; Nishizawa H; Yamamoto M; Yamada S; Takahashi Y
    Endocr J; 2013; 60(4):507-15. PubMed ID: 23291436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline.
    Biagetti B; Sarria-Estrada S; Ng-Wong YK; Martinez-Saez E; Casteràs A; Cordero Asanza E; Hernandez I; Giralt-Arnaiz M; Simò R
    Eur J Endocrinol; 2021 Sep; 185(4):587-595. PubMed ID: 34374649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression.
    Hurel SJ; Harris PE; McNicol AM; Foster S; Kelly WF; Baylis PH
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2962-5. PubMed ID: 9284727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
    Andrysiak-Mamos E; Kaźmierczyk-Puchalska A; Zochowska E; Sowińska-Przepiera E; Sagan L; Kojder I; Syrenicz A
    Pomeranian J Life Sci; 2015; 61(3):263-9. PubMed ID: 27344867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
    Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
    Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pasireotide: A potential therapeutic alternative for resistant prolactinoma.
    Lasolle H; Vasiljevic A; Borson-Chazot F; Raverot G
    Ann Endocrinol (Paris); 2019 Apr; 80(2):84-88. PubMed ID: 30318256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5.
    Gatto F; Barbieri F; Castelletti L; Arvigo M; Pattarozzi A; Annunziata F; Saveanu A; Minuto F; Castellan L; Zona G; Florio T; Ferone D
    Pituitary; 2011 Jun; 14(2):141-7. PubMed ID: 21086053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dopamine-agonist resistant prolactinomas: diagnosis and management].
    Musolino NR; Passos VQ
    Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):641-50. PubMed ID: 16444347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?
    Espinosa-Cárdenas E; Sánchez-García M; Ramírez-Rentería C; Mendoza-Zubieta V; Sosa-Eroza E; Mercado M
    Endocrine; 2020 Oct; 70(1):143-149. PubMed ID: 32548734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
    World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.